Ampio provides regulatory update

Englewood, colo. , april 20, 2022 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today announced the receipt of written responses from the united states food and drug administration (fda) pursuant to a type c meeting request submitted by the company earlier in the year regarding the ap-013 trial results.
AMPE Ratings Summary
AMPE Quant Ranking